Arthritis & Rheumatology · IF 11.4 · July 20, 2026 · LoE I
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz — Swedish Medical Center
This phase 3 randomized controlled trial (POETYK PsA-2) tested deucravacitinib, a first-in-class oral selective TYK2 inhibitor, against placebo (with apremilast included only as a safety reference) in 729 adults with active psoriatic arthritis who were biologic-naive or had limited prior TNF inhibitor exposure. By week 16, significantly more patients on deucravacitinib achieved an ACR20 response than those on placebo (54.2% vs 39.4%, p=0.0002), and improvements in joint disease, skin disease (PASI75), physical function (HAQ-DI), and quality of life were sustained through 52 weeks with a stable, well-tolerated safety profile and no new safety signals.
AI summary · from the full text · reviewed by Pukhraj Gaheer, Medical Student, Queen's University before publishing
Why it mattersDeucravacitinib offers an oral, non-biologic option with a novel mechanism (TYK2 regulatory-domain inhibition) and durable 1-year efficacy and safety data for psoriatic arthritis, a disease frequently co-managed by rheumatology and orthopaedic/joint specialists.
Conclusion strengthConfirms prior evidence
Patient-important outcome and adequately powered, offset by more patients lost than the result can absorb and industry funded with author conflicts.
Presenting this at rounds? Start here
- ?The prespecified hierarchical (fixed-sequence) testing broke at enthesitis resolution, which did not reach significance at week 16, meaning all subsequent 'secondary' endpoints (dactylitis, DAS28-CRP, FACIT-Fatigue) are only reported as nominal, unadjusted p-values; how much weight should readers give these downstream results?
- ?Since apremilast was included only as a safety reference with no formal efficacy comparison to deucravacitinib, what can clinicians actually conclude about how this drug should be positioned relative to apremilast or biologics already in use for psoriatic arthritis?